Welcome to the e-CCO Library!

P312: Has IBD specialists’ awareness of biosimilar monoclonal antibodies changed? Results from a survey amongst ECCO members
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Danese*1, 2, G. Fiorino1, P. Michetti3

Created: Friday, 22 February 2019, 9:49 AM
P312: Retrospective study using ultrasonography in predicting clinical relapse of Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Fukushima, S.(1)*;Katsurada, T.(1);Keiya, A.(1);Sakurai, K.(1);Yamanashi, K.(2);Omotehara, S.(3);Onishi, R.(1);Nishida, M.(3);Sakamoto, N.(1);
Created: Friday, 14 July 2023, 11:05 AM
P312: The value of faecal biomarkers for screening small bowel inflammation in patients with Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Yamamoto*, T. Shimoyama, S. Umegae

Created: Thursday, 21 February 2019, 9:14 AM
P312: Trabecular bone score in patients with inflammatory bowel diseases
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Krajcovicova A., Hlavaty T., Killinger Z., Kuzma M., Sturdik I., Leskova Z., Payer J.

Created: Wednesday, 20 February 2019, 10:36 AM
P313 Time to second pouchitis episode in a Dutch academic cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D.C. de Jong1, K. Wasmann2, C. Buskens2, W. Bemelman2, M. Löwenberg1, K. Gecse1, C. Ponsioen1, G. D’Haens1, R. Hompes2, M. Duijvestein1

Created: Thursday, 30 January 2020, 10:12 AM
P313: Comparison of accelerated infliximab induction versus standard induction treatment in acute severe ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Choy*1, 2, 3, D. Seah1, 3, A. Gorelik4, F. Macrae5, M. Sparrow6, W. R. Connell2, G. Moore7, D. Van Langenberg8, P. De Cruz1, 3

Created: Friday, 22 February 2019, 9:49 AM
P313: Glycan antibodies and pANCA in newly diagnosed inflammatory bowel disease patients at presentation and during follow-up
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Smids C.*1, Horjus Talabur Horje C.1, Groenen M.1, van Koolwijk E.2, Wahab P.1, van Lochem E.2

Created: Wednesday, 20 February 2019, 10:36 AM
P313: Impact of upadacitinib on the general clinical condition of patients with Crohn’s disease (CD): data from the randomised CELEST study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. V. Loftus Jr*1, D. T. Rubin2, J. Panes3, D. Pugatch4, W. Zhou4, S. Goteti4, A. Lacerda4, S. Travis5

Created: Friday, 22 February 2019, 9:41 AM
P313: Long-term durability and safety of anti-TNF agents compared with change to a different mechanism of action as a second-line biological treatment after first anti-TNF failure in Crohn´s disease: results from the Andalusian CambiaCrohn study
Year: 2021
Source: ECCO'21 Virtual
Authors: Vázquez Morón, J.M.(1);Martínez Rodríguez, M.D.M.(2);Olmedo Martin, R.(3);Hernández Martínez, Á.(4);Núñez Ortiz, A.(5);Rueda Sánchez, J.(6);Argüelles Arias, F.(7);Caballero Mateos, A.(8);Iglesias Flores, E.(9);Viejo Almanzor, A.(10);Pallarés Manrique, H.(11);
Created: Wednesday, 2 June 2021, 4:12 PM
P313: Steroid and opioid use among Crohn’s patients before and after initiation of ustekinumab
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Obando1*, K. Woodruff1, E. Muser1, C. Gasink1, T. Hoops1, T. Slaton2, C.M. Kozma2

Created: Thursday, 21 February 2019, 9:14 AM
P313: Understanding Inflammatory Bowel Disease patients' experiences, expectations, and insights in identifying and managing anxiety and depression.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Zelinsky, S.(1)*;Daley, K.(2);Patel, A.(3);Jeffs, L.(4);Zeng, L.(5);Targownik, L.(3);
Created: Friday, 14 July 2023, 11:05 AM
P313: Within 6 months from COVID-19 BNT162b2 vaccine patients with Inflammatory Bowel Diseases treated with Anti-TNFα have significantly lower serologic responses
Year: 2022
Source: ECCO'22
Authors: Rabinowitz, K.M.(1,2);Navon, M.(3);Edelman-Klapper, H.(1,4);Zittan, E.(5,6);Bar-Gil Shitrit, A.(7,8);Goren, I.(1,4);Avni-Biron, I.(1,4);Ollech, J.E.(1,4);Lichtenstein, L.(9);Banai-Eran, H.(1,4);Yanai, H.(1,4);Snir, Y.(1,4); Pauker, M.H.(1);Friedenberg, A.(1);Levy-Barda, A.(10);Segal, A.(11);Broitman, Y.(1,4);Maoz, E.(12);Ovadia, B.(13);Aharoni Golan, M.(1);Shachar, E.(4,14);Ben-Horin, S.(4,14);Perets, T.T.(15,16);Ben Zvi, H.(17);Eliakim, R.(4,14);Barkan, R.(1);Goren, S.(18);Krugliak, N.(3);Werbner, M.(19);Alter, J.(20);Dessau, M.(20);Gal-Tanamy, M.(19);Cohen, D.(18);Freund, N.T.(3);Dotan, I.(1,4);
Created: Friday, 11 February 2022, 3:52 PM
P314 C-Reactive protein is associated with depression and anxiety in patients with inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Rodriguez, J. Karpin, C. Traboulsi, V. Rai, D. Rubin

Created: Thursday, 30 January 2020, 10:12 AM
P314: Elderly onset is associated with low efficacy of anti-TNF treatment in Bio-naïve IBD patients: A multicenter cohort study by the Osaka Gut Forum
Year: 2022
Source: ECCO'22
Authors: Amano, T.(1);Shinzaki, S.(1);Asakura, A.(1);Tashiro, T.(1);Otake, Y.(1);Tani, M.(1);Yoshihara, T.(1);Inoue, T.(1);Takehara, T.(1);
Created: Friday, 11 February 2022, 3:52 PM
P314: Long-term fate of the excluded rectum in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Yzet*1, G. Kassim2, N. Nair2, J-F. Colombel2, D. B. Sachar2

Created: Friday, 22 February 2019, 9:41 AM
P314: Management of perianal disease in patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Algaba A.*1, Rubín de Célix C.1, Guerra I.1, Serrano A.2, Pérez-Viejo E.2, Aullό C.3, Hernández-Tejero M.1, Granja A.1, Bermejo F.1

Created: Wednesday, 20 February 2019, 10:36 AM
P314: Microscopic appendicitis in ulcerative colitis: Feasibility of ultrasonographic diagnosis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Reijntjes, M.(1)*;Pruijt, M.(2);Visser, E.(1);de Voogd, F.(2);d'Haens, G.R.(2);Mookhoek, A.(3);Gecse, K.B.(2);Buskens, C.J.(1);Bemelman, W.A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P314: MRI fistulography
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Sahnan1*, S.O. Adegbola1, P.J. Tozer1, A. Gupta2, J. Warusavitarne1, O.D. Faiz1, A.L. Hart3, R.K. Phillips1, P.F. Lung2

Created: Thursday, 21 February 2019, 9:14 AM
P314: Proposal for an anti-tumour necrosis factor–exit strategy based on trough serum level
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

U. Helwig*1, F. Lutter1, N. Koppka2, S. Schreiber3

Created: Friday, 22 February 2019, 9:49 AM
P314: TNF gene activation used as criterion to discontinue biologic therapy – A patient series introducing the NovaPrime TNF kit
Year: 2021
Source: ECCO'21 Virtual
Authors: Goll, R.(1);Kay-Martin, J.(1);Viola, A.(2);Paulssen, E.(1);Moe, Ø.K.(1);Cui, G.(3);Fries, W.(2);Florholmen, J.(4);
Created: Wednesday, 2 June 2021, 4:12 PM